May 21, 2013
Abbott today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and clinical outcomes of the XIENCE family of drug eluting stents in a...
May 20, 2013
- A packed programme is promised for EHRA EUROPACE 2013 meeting, taking place in Athens, Greece, 23 to 26 June, with the results of ten late breaking clinical trials and over 1000 original abstracts featured, offering exciting opportunities for news stories. The biennial meeting, which for the first time represents a collaboration between the European Heart Rhythm Association (EHRA) of the ESC and the ESC Working Groups on Cardiac Cellular Electrophysiology and e-Cardiology, promises to be more...
May 14, 2013
- Chronic pain is invisible, but for the people suffering from this hard-to-treat problem, it can be overwhelming. In the IMI project EUROPAIN, scientists from research institutions, universities and pharmaceutical companies have come together to learn more about the basic biology behind chronic pain. This will create a solid knowledge base to speed the development of drugs, known as analgesics, to treat pain. Around one in five adults in Europe have chronic (long-term) pain, i.e. lasting for...
May 13, 2013
The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan designation need to inform the Agency of their intention to submit an application in order to be eligible for a fee reduction. This forms part of the Agency's effort to reduce administrative burden for applicants and...
May 10, 2013
- 6 - 7 June 2013, Paris, France.
The activities at Doctors 2.0 & You will include +70 Speakers, presenting real-life examples of the use of healthcare social media and applications. Additional animations will include 13 start-ups, 15 poster presenters, and the exhibitors. Speakers come from 20 countries across Europe, the Middle East, North America, Asia, and Australia. They include 19 practicing healthcare professionals and 15 ePatients. Over 30 of the +70 speakers have created...
May 8, 2013
- Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria. The grant, provided by the Bill & Melinda Gates Foundation, allows the three groups to work together to develop scalable methods to enable large-scale...
May 7, 2013
Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Alliance for Europe (SAFE) and Bayer HealthCare jointly raise their voices that society cannot afford not to prevent cardiovascular diseases. As the worldwide leading cause of death, the consequences of cardiovascular disease are immense. Cardiovascular disease has no geographic...
May 6, 2013
- IMI's EU-AIMS (European Autism Interventions - A Multicentre Study for Developing New Medications) project is making breakthroughs in research into autism spectrum disorder (ASD), that are set to make a real difference to the lives of people with autism and their families. ASD affects around one in a hundred children, but still has no effective drug treatments. ASD symptoms include problems with social interactions, behaviour, co-ordination, language and communication. These range from mild to...
May 3, 2013
- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients....
May 2, 2013
- Following the recent recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) has endorsed by majority the PRAC recommendation to suspend the marketing authorisations of tetrazepam-containing medicines across the...